Despite the high prevalence of major depressive disorder and the related societal burden, access to effective traditional face-to-face or video-based psychotherapy is a challenge. An alternative that offers mental health care in a flexible setting is asynchronous messaging therapy. To date, no study has evaluated its efficacy and acceptability in a randomized controlled trial for depression.
The aim of this study was to compare the efficacy and acceptability of message-based psychotherapy for depression to once-weekly video-based psychotherapy.
In this 2-armed randomized controlled trial, individuals (N=83) with depressive symptomatology (Patient Health Questionnaire-9 ≥10) were recruited on the internet and randomly assigned to either a message-based intervention group (n=46) or a once-weekly video-based intervention group (n=37). Patients in the message-based treatment condition exchanged asynchronous messages with their therapist following an agreed-upon schedule. Patients in the video-based treatment condition met with their therapist once each week for a 45-minute video teletherapy session. Self-report data for depression, anxiety, and functional impairment were collected at pretreatment, weekly during treatment, at posttreatment, and at a 6-month follow-up. Self-reported treatment expectancy and credibility for the assigned intervention were assessed at pretreatment and therapeutic alliance at posttreatment.
Findings from multilevel modeling indicated significant, medium-to-large improvements in depression ( d=1.04; 95% CI 0.60-1.46), anxiety ( d=0.61; 95% CI 0.22-0.99), and functional impairment ( d=0.66; 95% CI 0.27-1.05) for patients in the message-based treatment condition. Changes in depression ( d=0.11; 95% CI –0.43 to 0.66), anxiety ( d=–0.01; 95% CI –0.56 to 0.53), and functional impairment ( d=0.25; 95% CI –0.30 to 0.80) in the message-based treatment condition were noninferior to those in the video-based treatment condition. There were no significant differences in treatment credibility ( d=–0.09; 95% CI –0.64 to 0.45), therapeutic alliance ( d=–0.15; 95% CI –0.75 to 0.44), or engagement ( d=0.24; 95% CI –0.20 to 0.67) between the 2 treatment conditions.